Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Arcus Capital Partners LLC boosted its position in Meta Platforms, Inc. (NASDAQ:META – Free Report) by 6.9% during the fourth ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented ...

In trading on Tuesday, shares of Arcus Biosciences Inc (Symbol: RCUS) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $13.08 per share. By ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...